Background
==========

Amniotic fluid increases in volume as the foetus grows and peaks at an average of 800 mL at approximately 34 weeks of gestation. Approximately 600 mL of amniotic fluid surrounds the baby at full term (40 weeks). This fluid is circulated constantly by the baby inhaling and swallowing existing fluid and replacing it through exhalation and urination \[[@B1]\]. Amniotic fluid accomplishes numerous functions: (1) it protects the foetus from injury by cushioning sudden blows or movements, (2) it enables foetal movement and symmetrical musculoskeletal development, (3) it maintains a relatively constant temperature and thus protects the foetus from heat loss, and (4) it ensures proper foetal lung development \[[@B1],[@B2]\].

Low levels of magnesium in amniotic fluid are associated with pregnancy complications such as preeclampsia \[[@B3]\] and diabetes \[[@B4],[@B5]\]. Magnesium supplements have been demonstrated to reduce the frequency of delayed foetal growth, especially in low-birth-weight babies. However, the general benefits of magnesium for foetal growth and development have not been demonstrated \[[@B6]\]; the Magpie study \[[@B7]\], for example, concluded that treatment with magnesium did not improve preeclampsia.

Consequently, knowledge of the values for this ion in normal amniotic fluid may provide a preventive and early diagnosis of certain maternal and foetal pathologies. Amniocentesis is performed, if indicated, from the second trimester of pregnancy. Although magnesium values in amniotic fluid \[[@B8]-[@B11]\] are reported in the literature, no reference values are provided for the three different pregnancy trimesters.

Magnesium in serum is reduced during pregnancy and so additional magnesium is required in the diet \[[@B6],[@B12],[@B13]\]. The recommended daily intake for pregnant women is higher than for the same age group of non-pregnant woman, yet most pregnant women do not consume the required amount \[[@B6]\].

Because variations in magnesium values could be useful as diagnostic and therapeutic guidelines for possible complications, our aim was to determine magnesium levels in amniotic fluid so as to establish normal values for the 14-to-18-week interval of the second trimester of pregnancy.

Methods
=======

The study design and protocol were reviewed and approved by the \"Ethics Committee of Hospital Universitario Miguel Servet\" in accordance with the Declaration of Helsinki and the Nuremberg Code. All the patients in the study granted their informed consent.

Included in the study were 92 pregnant women aged between 21 and 44 years old. Sample size was established on the basis of the mean number of pregnant women undergoing amniocentesis between the 14^th^and 18^th^week of pregnancy. The average gestational age at which amniotic fluid samples were obtained by amniocentesis was 16.13 (±1.87) weeks. The extracted amniotic fluid samples were sent immediately to the laboratory for centrifugation and processing to determine magnesium levels, or, if immediate processing was not possible, they were stored at -80°C. The reasons for performing amniocentesis on the patients in our sample are summarized in Figure [1](#F1){ref-type="fig"}.

![**Reasons for performing amniocentesis in pregnant women**.](1756-0500-4-185-1){#F1}

Magnesium levels were analysed for both the amniotic fluid and serum of the study population, by colorimetric assay with chlorophosphonazo-III using the Cobas c 501 analyser (Roche Diagnostics). The measurement interval was 0.24-6.08 mg/dL and the lower detection threshold was 0.24 mg/dL. The reference serum value for the normal adult population (21-59 years) was 1.6-2.6 mg/dL. Statistical analysis was performed using the SPSS program, version 15.0.

Results and discussion
======================

Results revealed a mean amniotic fluid value of 1.65 ± 0.16 mg/dL\--with the value 1.6 mg/dL repeated in many samples\--and a mean serum value of 1.97 ± 0.23 mg/dL. Amniotic fluid values for magnesium were slightly lower than serum values. No variations in magnesium levels were detected in patients referred for amniocentesis to diagnose disorders that could imply a risk for the foetus. Similarly, despite variations in amniotic fluid volume during pregnancy \[[@B1]\], magnesium concentrations remained fairly stable.

These results are consistent with previous studies \[[@B8]-[@B11]\] analysing magnesium levels in amniotic fluid; however, these studies did not distinguish between the three trimesters of pregnancy.

Falls in amniotic fluid magnesium levels are associated with pregnancy complications such as preeclampsia \[[@B3]\] and diabetes \[[@B4],[@B5]\]. Magnesium sulphate, which has a specific maternal central nervous system anticonvulsant action, has gained wide international acceptance as an effective drug for the treatment of eclampsia \[[@B14]\]; however, magnesium treatment does not appear to be effective in preventing preeclampsia. Maternal hypoxia and convulsions, eclampsia and epileptic seizures can have a neurotoxic effect on the foetus. Magnesium sulphate may also protect low-birth-weight infants (under 1500 g) against cerebral palsy \[[@B15]\]. Magnesium is also considered an important factor in the pathogenesis of toxic shock syndrome; according to one study \[[@B15]\], toxin 1 production by *Staphylococcus aureus*was maximal when magnesium concentrations were low, while higher concentrations suppressed toxin 1 production. On the other hand, magnesium sulphate, when given in high dosages to obstetric patients, can cause significant maternal morbidity and rare instances of maternal mortality \[[@B14]\].

Conclusions
===========

Despite the risk associated with amniocentesis, it would be interesting to extend the study to a larger number of pregnant women and determine magnesium values for the first, second and third trimesters in both normal and abnormal pregnancies, so as to establish normal values and critical ranges and better evaluate complications and their management.
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